HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study.

AbstractBACKGROUND:
Oral mucositis is a frequent and serious complication in patients receiving chemo-radiotherapy for head and neck squamous cell carcinoma. This study evaluated the effects of administering Lactobacillus brevis CD2 lozenges on the incidence and severity of mucositis and tolerance to chemo-radiotherapy.
METHODS:
Two hundred patients suitable for chemo-radiotherapy were enrolled in a randomised, double-blind study to receive daily treatment with lozenges containing either L. brevis CD2 or placebo. Anticancer therapy was RT 70 Grays/35 fractions over 7 weeks with weekly Inj. Cisplatin 40 mg/m(2). The study treatment was given during, and for 1 week after completion of anticancer therapy. Primary end-points were the incidence of grade III and IV oral mucositis and the percentage of patients able to complete anticancer treatment.
FINDINGS:
The efficacy analysis included the 188 patients who received ≥ 1 week of study treatment. Grade III and IV mucositis developed in 52% of patients in the L. brevis CD2 arm and 77% in the placebo arm (P<0.001). Anticancer treatment completion rates were 92% in the L. brevis CD2 arm and 70% in the placebo arm (P=0.001). A larger proportion of patients remained free of mucositis when treated with L. brevis CD2 (28%) compared to the placebo (7%).
INTERPRETATION:
L. brevis CD2 lozenges reduced the incidence of grade III and IV anticancer therapy-induced oral mucositis and were associated with a lower overall rate of mucositis and a higher rate of anticancer treatment completion.
AuthorsAtul Sharma, G K Rath, S P Chaudhary, Alok Thakar, Bidhu Kalyan Mohanti, Sudhir Bahadur
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 48 Issue 6 Pg. 875-81 (Apr 2012) ISSN: 1879-0852 [Electronic] England
PMID21741230 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2011 Elsevier Ltd. All rights reserved.
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Carcinoma, Squamous Cell (therapy)
  • Chemoradiotherapy (adverse effects)
  • Double-Blind Method
  • Female
  • Head and Neck Neoplasms (therapy)
  • Humans
  • Incidence
  • India (epidemiology)
  • Lactobacillus brevis
  • Male
  • Middle Aged
  • Mouth Mucosa (drug effects, radiation effects)
  • Stomatitis (epidemiology, etiology, prevention & control)
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: